Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Precipio, Inc. PRPO

Healthcare  —  Diagnostics & Research
23.65 (0.82) (3.35%) as of 25 Sep
Market cap
$43.8M
P/E
0.0×
Cash Flow Champion (3y) Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Precipio, Inc. (PRPO) Business Profile

Updated before January 2025

Company Overview

Precipio, Inc. (NASDAQ: PRPO) is a healthcare solutions company specializing in the development and delivery of innovative diagnostic technologies. Founded in 2011 and headquartered in New Haven, Connecticut, Precipio aims to address the challenges of diagnostic errors in the healthcare industry. The company was established with a mission to improve patient outcomes by providing accurate and timely diagnostic information. Precipio’s leadership team includes experienced professionals from the healthcare and biotechnology sectors, with Ilan Danieli serving as the Chief Executive Officer. Under his guidance, the company has grown into a trusted name in the diagnostic industry.

Core Business Segments

Diagnostic Products

Precipio offers a range of diagnostic products designed to enhance the accuracy of disease detection. These include:

  • HemeScreen™: A proprietary diagnostic platform that simplifies and accelerates the detection of hematologic malignancies, such as leukemia and lymphoma.
  • IV-Cell™: A cell culture media product that improves the accuracy of cytogenetic testing.

Laboratory Services

Precipio operates a CLIA-certified laboratory that provides specialized diagnostic services. These services include:

  • Pathology Services: Comprehensive pathology testing for oncology and hematology.
  • Molecular Diagnostics: Advanced testing for genetic mutations and biomarkers.

Technology Licensing

Precipio licenses its proprietary technologies to other laboratories and healthcare providers, enabling them to improve their diagnostic capabilities.

Business Model

Precipio’s business model revolves around integrating innovative diagnostic products and services to address the needs of healthcare providers and patients. The company generates revenue through the sale of diagnostic products, laboratory testing services, and technology licensing agreements. By focusing on accuracy and efficiency, Precipio aims to reduce diagnostic errors and improve patient outcomes. The company also collaborates with academic institutions and research organizations to develop cutting-edge diagnostic technologies.

Strategic Direction

Precipio is committed to expanding its product and service offerings to meet the evolving needs of the healthcare industry. Key strategic initiatives include:

  • Product Expansion: Developing new diagnostic platforms and enhancing existing products like HemeScreen™ and IV-Cell™.
  • Market Penetration: Increasing its presence in domestic and international markets through strategic partnerships and distribution agreements.
  • Sustainability Goals: Implementing eco-friendly practices in product development and laboratory operations.
  • Innovation: Investing in research and development to stay ahead of industry trends and introduce groundbreaking diagnostic solutions.

Competitive Landscape

Precipio operates in a highly competitive market, facing competition from both established players and emerging startups. Key competitors include:

  • Thermo Fisher Scientific: A global leader in diagnostic technologies and laboratory services.
  • Quest Diagnostics: A major provider of diagnostic testing and services.
  • Bio-Rad Laboratories: Known for its innovative diagnostic products and solutions.
  • NeoGenomics Laboratories: Specializes in cancer-focused genetic testing and pathology services.

Despite the competition, Precipio differentiates itself through its proprietary technologies and focus on reducing diagnostic errors.

Risk Factors

Precipio faces several risks that could impact its operations and financial performance, including:

  • Market Dependence: Reliance on the healthcare sector and diagnostic testing demand.
  • Supply Chain Disruptions: Potential delays in obtaining raw materials and components for product manufacturing.
  • Regulatory Challenges: Compliance with stringent healthcare regulations and approval processes.
  • Competition: Intense competition from larger, well-established companies.

Recent Developments

Precipio has made significant strides in recent years, including:

  • HemeScreen™ Expansion: Launching additional panels to broaden the scope of hematologic testing.
  • Partnerships: Collaborating with leading healthcare providers to expand its market reach.
  • COVID-19 Impact: Adapting its operations to address the challenges posed by the pandemic, including supply chain disruptions and increased demand for diagnostic testing.

Investment Considerations

Strengths

  • Proprietary technologies like HemeScreen™ and IV-Cell™.
  • Focus on reducing diagnostic errors and improving patient outcomes.
  • Experienced leadership team and strong industry partnerships.

Risks

  • Dependence on a limited number of products and services.
  • Exposure to regulatory and competitive pressures.
  • Potential supply chain disruptions.

Conclusion

Precipio, Inc. is a dynamic player in the diagnostic industry, leveraging innovative technologies to address critical challenges in healthcare. With a strong focus on accuracy and efficiency, the company is well-positioned to capitalize on growth opportunities in the diagnostic market. While it faces risks such as competition and regulatory hurdles, Precipio’s commitment to innovation and strategic expansion provides a solid foundation for future success.